Literature DB >> 25173540

Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study.

Aaron R Folsom1, Alvaro Alonso2, Jeffrey R Misialek2, Erin D Michos3, Elizabeth Selvin4, John H Eckfeldt5, Josef Coresh6, James S Pankow2, Pamela L Lutsey2.   

Abstract

BACKGROUND: According to a recent meta-analysis, parathyroid hormone (PTH) excess is associated with increased cardiovascular disease (CVD) risk, but existing studies are limited. We examined in a prospective study the association of PTH with the incidence of CVD, taking into account vitamin D and other confounding variables.
METHODS: The ARIC study measured PTH using a second-generation assay (Roche, Indianapolis, IN) in stored serum samples from 1990 to 1992 and related levels in 10,392 adults to incident cardiovascular outcomes (coronary heart disease [n = 808], heart failure [n = 1,294], stroke [n = 586], peripheral artery disease [n = 873], atrial fibrillation [n = 1,190], and CVD mortality [n = 647]) through 2010 (median follow-up 19 years).
RESULTS: Contrary to the hypothesis, PTH level was not associated positively with any CVD outcome. The associations of incident heart failure, peripheral artery disease, and CVD mortality with PTH actually were weakly inverse (P trend = .02-.04) in the most fully adjusted models. For example, the hazard ratios across PTH quartiles were 1.00, 1.07, 1.07, and 0.96 (P trend = .74) for coronary heart disease incidence and were 1.00, 0.69, 0.74, and 0.74 (P trend = .02) for CVD mortality. Patterns were similar when restricted to participants with normal baseline kidney function.
CONCLUSIONS: This large prospective study failed to support the hypothesis that elevated PTH is an independent risk marker for incident CVD. When our data were added to the previous meta-analysis, the pooled hazard ratio remained statistically significant but weakened.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25173540      PMCID: PMC4150218          DOI: 10.1016/j.ahj.2014.04.017

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  33 in total

1.  Peripheral vascular disease risk factors among patients undergoing hemodialysis.

Authors:  Ann M O'Hare; Chi-Yuan Hsu; Peter Bacchetti; Kirsten L Johansen
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

2.  The National Survey of Stroke. National Institute of Neurological and Communicative Disorders and Stroke.

Authors: 
Journal:  Stroke       Date:  1981 Mar-Apr       Impact factor: 7.914

3.  A short questionnaire for the measurement of habitual physical activity in epidemiological studies.

Authors:  J A Baecke; J Burema; J E Frijters
Journal:  Am J Clin Nutr       Date:  1982-11       Impact factor: 7.045

4.  Vitamin D-binding protein and vitamin D status of black Americans and white Americans.

Authors:  Camille E Powe; Michele K Evans; Julia Wenger; Alan B Zonderman; Anders H Berg; Michael Nalls; Hector Tamez; Dongsheng Zhang; Ishir Bhan; S Ananth Karumanchi; Neil R Powe; Ravi Thadhani
Journal:  N Engl J Med       Date:  2013-11-21       Impact factor: 91.245

Review 5.  Primary hyperparathyroidism and heart disease--a review.

Authors:  Patrik Andersson; Erik Rydberg; Ronnie Willenheimer
Journal:  Eur Heart J       Date:  2004-10       Impact factor: 29.983

6.  Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA.

Authors:  W F Rigby; S Denome; M W Fanger
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

7.  Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells.

Authors:  Vlado Perkovic; Timothy D Hewitson; Kristen J Kelynack; Marina Martic; Melanie G Tait; Gavin J Becker
Journal:  Kidney Blood Press Res       Date:  2003       Impact factor: 2.687

8.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

9.  Parathyroid hormone and left ventricular hypertrophy.

Authors:  F N Saleh; H Schirmer; J Sundsfjord; R Jorde
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

10.  Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis.

Authors:  José Luis Martín-Ventura; Mónica Ortego; Pedro Esbrit; Miguel Angel Hernández-Presa; Luis Ortega; Jesús Egido
Journal:  Stroke       Date:  2003-06-12       Impact factor: 7.914

View more
  18 in total

1.  Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study.

Authors:  Laura M G Meems; Frank P Brouwers; Michel M Joosten; Hiddo J Lambers Heerspink; Dick de Zeeuw; Stephan J L Bakker; Ron T Gansevoort; Wiek H van Gilst; Pim van der Harst; Rudolf A de Boer
Journal:  ESC Heart Fail       Date:  2016-04-26

2.  Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer.

Authors:  Yasuhiko Kubota; Kelly R Evenson; Richard F Maclehose; Nicholas S Roetker; Corinne E Joshu; Aaron R Folsom
Journal:  Med Sci Sports Exerc       Date:  2017-08       Impact factor: 5.411

3.  Association of Educational Attainment With Lifetime Risk of Cardiovascular Disease: The Atherosclerosis Risk in Communities Study.

Authors:  Yasuhiko Kubota; Gerardo Heiss; Richard F MacLehose; Nicholas S Roetker; Aaron R Folsom
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873

4.  25-Hydroxyvitamin D insufficiency discriminates cardiovascular risk factors accumulation in peri-pubertal boys undergoing overweight screening.

Authors:  Andrea Di Nisio; Luca De Toni; Elvio D'Addato; Maria R Pizzo; Pasquale Sabatino; Carlo Foresta
Journal:  Endocrine       Date:  2015-09-01       Impact factor: 3.633

5.  Kidney function, bone-mineral metabolism markers, and future risk of peripheral artery disease.

Authors:  Chao Yang; Lucia Kwak; Shoshana H Ballew; Pranav S Garimella; Bernard G Jaar; Aaron R Folsom; Gerardo Heiss; Elizabeth Selvin; Pamela L Lutsey; Josef Coresh; Kunihiro Matsushita
Journal:  Atherosclerosis       Date:  2017-09-22       Impact factor: 5.162

6.  Independent and Synergistic Associations of Biomarkers of Vitamin D Status With Risk of Coronary Heart Disease.

Authors:  Lu Qi; Wenjie Ma; Yoriko Heianza; Yan Zheng; Tiange Wang; Dianjianyi Sun; Eric B Rimm; Frank B Hu; Edward Giovannucci; Christine M Albert; Kathryn M Rexrode; JoAnn E Manson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-09-07       Impact factor: 8.311

7.  Serum calcium and incident type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Mary R Rooney; James S Pankow; Shalamar D Sibley; Elizabeth Selvin; Jared P Reis; Erin D Michos; Pamela L Lutsey
Journal:  Am J Clin Nutr       Date:  2016-08-10       Impact factor: 7.045

8.  Parathyroid Hormone and Subclinical Cerebrovascular Disease: The Atherosclerosis Risk in Communities Brain Magnetic Resonance Imaging Study.

Authors:  Sai Krishna C Korada; Di Zhao; Rebecca F Gottesman; Eliseo Guallar; Pamela L Lutsey; Alvaro Alonso; A Richey Sharrett; Wendy S Post; Jared P Reis; Thomas H Mosley; Erin D Michos
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-01-26       Impact factor: 2.136

9.  Vitamin D deficiency--prognostic marker or mortality risk factor in end stage renal disease patients with diabetes mellitus treated with hemodialysis--a prospective multicenter study.

Authors:  Adalbert Schiller; Florica Gadalean; Oana Schiller; Romulus Timar; Flaviu Bob; Mircea Munteanu; Dana Stoian; Adelina Mihaescu; Bogdan Timar
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

10.  Association of parathyroid hormone with 20-year cognitive decline: The ARIC study.

Authors:  Samuel M Kim; Di Zhao; Andrea L C Schneider; Sai Krishna Korada; Pamela L Lutsey; Eliseo Guallar; Alvaro Alonso; B Gwen Windham; Rebecca F Gottesman; Erin D Michos
Journal:  Neurology       Date:  2017-08-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.